What is SNY's current stock price?

As of now, SNY is trading at $49.52, with a daily change of -0.94%.

What are the risks associated with SNY stock?

SNY Key risk is its Low Risk Level, .

What is SNY next earnings date?

SNY next earnings report is scheduled for Oct 24, 2025.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

SNY Stock Analysis & IQ Rating | Sanofi

SNY

Sanofi

$49.52

-$0.47 | -0.94%

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 60.12

MKT CAP

$ 122.50B

52W Low

$ 44.62

VOL

$ 2.79M

P/E Ratio

11.63

AVG VOL

$ 3.52M

RSI

TREND

SNY Stock IQ

Login to see Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

SNY Target Price

Login to display

Strengths

SNY Rewards

Earnings are forecast to grow

SNY Rewards

Trading below its fair value

Chart

$45.54 (+8.74%)

$45.66 (+8.45%)

$49.19 (+0.67%)

$51.26 (-3.39%)

1year

6month

3month

1month

SNY Risk Level

SNY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

LOW

HIGH

SNY Analysts Opinion

SNY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

SNY Analysts Opinion

SNY Analysts opinion is negative and it remained unchanged from the past 3 months

SNY Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

90%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

33%

100%

SNY Street Opinion

SNY Street view is extremely bullish and have positive views on the near-term outlook

SNY Performance Sentiment

Sentiments overview associated with SNY events and the stock performance.

90%

10%

Positive

Negative

26 out of 29
events present

3 out of 29
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$50.62

Resistance
Price

$45.07

Current Price Range

$50.90

Show methods +

SNY Earnings

The TTM reflects 12-month period, providing review of SNY financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

45,738

44,286

41,618

+4.83%

Cost of Revenue

13,120

13,205

12,628

+1.93%

Gross Profit

32,618

31,081

28,990

+6.07%

Operating Exp

22,637

21,619

19,815

+6.88%

Operating Inc

9,981

9,462

9,175

+4.30%

Net Interest Inc

-432

-560

-706

-

Interest Exp

665

749

710

-3.22%

Interest Inc

336

413

527

-20.15%

Other Inc Exp

-1,731

-2,204

-2,218

-

EPS Growth

3.69

2.22

2.15

+31.01%

SNY Financial Health

The company financial health has shown minor improvement, but significant issues remain

Financial Score

3.42

Next Earnings Date: Oct 24, 2025

Linked to SNY

IQ

Close Price

Change

PFE

4.06

24.67

-0.22%

NVS

4.26

131.64

+0.15%

LLY

4.15

821.04

+1.06%

MRK

4.03

87.18

-0.55%

ABBV

4.14

228.25

-0.16%

SNY Latest Analysis +

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy. ) on Wednesday revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537 formerly known as INBRX-101) for alpha-1 antitrypsin .AATD causes emphysema when the body doesn’.t produce enough of the protective alpha-1 antitrypsin (AAT) protein leading to a breakdown of the lung’.s air sacs (alveoli).This genetic condition leads to the accumulation of enzymes such as neutro

Wed Oct 22, 2025

$49.99 | +0.66%

Activity

Potential

Sanofis Efdoralprin Alfa Meets All Endpoints In Phase 2 AATD Emphysema Study . (RTTNews) - Sanofi (SNY SNYNF SAN.PA) announced positive topline results from the global Phase 2 ElevAATe study evaluating efdoralprin alfa (SAR447537 formerly INBRX-101) in adults with alpha-1 antitrypsin deficiency (AATD) emphysema. The investigational recombinant human AAT-

Wed Oct 22, 2025

$49.99 | +0.66%

Activity

Sanofi Reports Superior Protection For Older Adults With High-Dose Influenza Vaccine . (RTTNews) - Sanofi SA (SNY) announced that new data from the FLUNITY-HD study showed its high-dose influenza vaccine significantly reduces the risk of hospitalization in adults aged 65 and older compared to standard-dose flu vaccines.

Mon Oct 20, 2025

$49.73 | -1.76%

Potential

Sanofi: FDA Accepts SBLA For Tzield For Expedited Review . (RTTNews) - Sanofi (SNY) said the FDA has accepted for expedited review the supplemental biologics license application for Tzield to delay the progression of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1D.

Mon Oct 20, 2025

$49.73 | -1.76%

Activity

Sanofis Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease. On Friday the European Medicines Agency'.s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for ) Rezurock (belumosudil).The French drug maker was seeking approval for Rezurock for the third-line treatment of adults and pediatric patients with chronic .cGVHD is considered one of the leading causes of morbidity and late non-relapse mortality after stem cell transplant. Sanofi will seek a

Fri Oct 17, 2025

$50.62 | +1.19%

Activity

Momentum

Sanofis Wayrilz Bags CHMP Recommendation For Immune Thrombocytopenia Treatment . (RTTNews) - Sanofi (SNY) Friday announced that the European Medicines Agencys Committee for Medicinal Products for Human Use or CHMP has recommended the approval of Wayrilz for the treatment of immune thrombocytopenia in adults.

Fri Oct 17, 2025

$50.62 | +1.19%

Activity

EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi. ...

Thu Oct 16, 2025

$50.02 | +2.17%

Activity

EVOQ Enters Collaboration And License Agreement With Sanofi . (RTTNews) - EVOQ Therapeutics Inc. announced a Collaboration and License Agreement with Sanofi (SNY). EVOQ is focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQs technology platform utilizes a synthetic HDL NanoDisc that

Thu Oct 16, 2025

$50.02 | +2.17%

Activity

RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes. Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection expanding its reach beyond rare diseases.

Thu Oct 9, 2025

$48.82 | +0.04%

Activity

BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS. ) (FRA: 5LB) (OTCQB:) (".BioVaxys". or ".Company".) is pleased to announce that Dr. Tartaglia is an internationally recognized vaccine R&.D leader with over 34 years of industry experience including contributions to partnerships with private sector government and international agencies. Dr. Tartaglia recently retired as Global Head of Vaccine Development and Life Cycle Management for Sanofi the global p

Wed Oct 8, 2025

$48.80 | -0.80%

Activity

FAQ About SNY Stock Insights

What is SNY current stock price?

What are SNY stock strengths?

What risks are associated with SNY stock?

When is SNY next earnings report?

What is SNY market cap and volume?

What is SNY's current Stock IQ?

Should I buy SNY stock right now?

Is SNY a Strong Buy right now?

What does a 'Strong Buy' rating mean for SNY?

What does a 'Strong Sell' rating mean for SNY?

What factors influence SNY's Stock IQ?

Explore our SNY Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored SNY Stock Strategies
Effective Risk Management

FIND US ON

Receive our SNY Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

SNY

Sanofi

Current Price

$49.52

-$0.47 | -0.94%

52W High

$ 60.12

MKT CAP

$ 122.50B

52W Low

$ 44.62

VOL

$ 2.79M

P/E Ratio

11.63

AVG VOL

$ 3.52M

RSI

TREND

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

SNY Rewards

Earnings are forecast to grow

SNY Rewards

Trading below its fair value

Linked to SNY

Symbol

IQ

Close

Change

PFE

4.06

24.67

-0.22%

NVS

4.26

131.64

+0.15%

LLY

4.15

821.04

+1.06%

MRK

4.03

87.18

-0.55%

ABBV

4.14

228.25

-0.16%

SNY Stock IQ

Login to unlock Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$45.54 (+8.74%)

$45.66 (+8.45%)

$49.19 (+0.67%)

$51.26 (-3.39%)

1year

6month

3month

1month

SNY Analysts Opinion

SNY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

SNY Analysts Opinion

SNY Analysts opinion is negative and it remained unchanged from the past 3 months

SNY Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

90%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

33%

100%

SNY Street Opinion

SNY Street view is extremely bullish and have positive views on the near-term outlook

SNY Risk Level

SNY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

LOW

HIGH

SNY Performance Sentiment

Sentiments overview associated with SNY events and the stock performance.

90%

10%

Positive

Negative

26 out of 29
events present

3 out of 29
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$50.62

Resistance
Price

$45.07

Current Price Range

$50.90

Show methods +

SNY Earnings

The TTM data reflects the most recent 12-month period, providing overview of SNY financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

45,738

44,286

41,618

+4.83%

Cost of Revenue

13,120

13,205

12,628

+1.93%

Gross Profit

32,618

31,081

28,990

+6.07%

Operating Exp

22,637

21,619

19,815

+6.88%

Operating Inc

9,981

9,462

9,175

+4.30%

Net Interest Inc

-432

-560

-706

-

Interest Exp

665

749

710

-3.22%

Interest Inc

336

413

527

-20.15%

Other Inc Exp

-1,731

-2,204

-2,218

-

EPS Growth

3.69

2.22

2.15

+31.01%

SNY Financial Health

The company financial health has shown minor improvement, but significant issues remain

Financial Score

3.42

Next Earnings Date: Oct 24, 2025

SNY Latest Analysis

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy. ) on Wednesday revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537 formerly known as INBRX-101) for alpha-1 antitrypsin .AATD causes emphysema when the body doesn’.t produce enough of the protective alpha-1 antitrypsin (AAT) protein leading to a breakdown of the lung’.s air sacs (alveoli).This genetic condition leads to the accumulation of enzymes such as neutro

Wed Oct 22, 2025

$49.99 | +0.66%

Activity

Potential

Sanofis Efdoralprin Alfa Meets All Endpoints In Phase 2 AATD Emphysema Study . (RTTNews) - Sanofi (SNY SNYNF SAN.PA) announced positive topline results from the global Phase 2 ElevAATe study evaluating efdoralprin alfa (SAR447537 formerly INBRX-101) in adults with alpha-1 antitrypsin deficiency (AATD) emphysema. The investigational recombinant human AAT-

Wed Oct 22, 2025

$49.99 | +0.66%

Activity

Sanofi Reports Superior Protection For Older Adults With High-Dose Influenza Vaccine . (RTTNews) - Sanofi SA (SNY) announced that new data from the FLUNITY-HD study showed its high-dose influenza vaccine significantly reduces the risk of hospitalization in adults aged 65 and older compared to standard-dose flu vaccines.

Mon Oct 20, 2025

$49.73 | -1.76%

Potential

Sanofi: FDA Accepts SBLA For Tzield For Expedited Review . (RTTNews) - Sanofi (SNY) said the FDA has accepted for expedited review the supplemental biologics license application for Tzield to delay the progression of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1D.

Mon Oct 20, 2025

$49.73 | -1.76%

Activity

Sanofis Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease. On Friday the European Medicines Agency'.s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for ) Rezurock (belumosudil).The French drug maker was seeking approval for Rezurock for the third-line treatment of adults and pediatric patients with chronic .cGVHD is considered one of the leading causes of morbidity and late non-relapse mortality after stem cell transplant. Sanofi will seek a

Fri Oct 17, 2025

$50.62 | +1.19%

Activity

Momentum

Sanofis Wayrilz Bags CHMP Recommendation For Immune Thrombocytopenia Treatment . (RTTNews) - Sanofi (SNY) Friday announced that the European Medicines Agencys Committee for Medicinal Products for Human Use or CHMP has recommended the approval of Wayrilz for the treatment of immune thrombocytopenia in adults.

Fri Oct 17, 2025

$50.62 | +1.19%

Activity

EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi. ...

Thu Oct 16, 2025

$50.02 | +2.17%

Activity

EVOQ Enters Collaboration And License Agreement With Sanofi . (RTTNews) - EVOQ Therapeutics Inc. announced a Collaboration and License Agreement with Sanofi (SNY). EVOQ is focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQs technology platform utilizes a synthetic HDL NanoDisc that

Thu Oct 16, 2025

$50.02 | +2.17%

Activity

RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes. Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection expanding its reach beyond rare diseases.

Thu Oct 9, 2025

$48.82 | +0.04%

Activity

BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS. ) (FRA: 5LB) (OTCQB:) (".BioVaxys". or ".Company".) is pleased to announce that Dr. Tartaglia is an internationally recognized vaccine R&.D leader with over 34 years of industry experience including contributions to partnerships with private sector government and international agencies. Dr. Tartaglia recently retired as Global Head of Vaccine Development and Life Cycle Management for Sanofi the global p

Wed Oct 8, 2025

$48.80 | -0.80%

Activity

Discover SNY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of SNY. We're here to help you make informed investment decisions today.

FIND US ON

Receive our SNY Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

SNY Stock trends

SNY Stock performance

SNY Stock analysis

SNY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

SNY Stock Analysis & IQ Rating | Sanofi

SNY Stock IQ

SNY Target Price

SNY Risk Level

SNY Analysts Opinion

SNY Street Consensus

SNY Performance Sentiment

Technical Price Levels

SNY Financial Health

Explore our SNY Stock insights

Receive our SNY Daily Alerts

SNY Stock IQ

SNY Street Consensus

SNY Risk Level

Technical Price Levels

Discover SNY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of SNY. We're here to help you make informed investment decisions today.

Receive our SNY Daily Alerts

SNY Runner Alarm